Latest Biotech News

Kura Oncology and Kyowa Kirin reported early data for oral menin inhibitors showing a 73% complete response rate in newly‑diagnosed patients with specific acute myeloid leukemia subtypes. The...

Researchers in Turkey described an implantable biosensor that uses genetically engineered E. coli to detect molecular signals in vivo and transmit data wirelessly without external batteries. The...

Cogent Biosciences reported that its Phase 3 study of bezuclastinib achieved the primary endpoint in patients with advanced systemic mastocytosis, including benefits in sicker patient subgroups....

Structure Therapeutics reported robust mid‑stage efficacy for its small‑molecule GLP‑1 candidate aleniglipron, with patients on higher doses losing as much as 14.2% of body weight at 36 weeks. The...

China’s Ascletis reported phase 2 topline data from a U.S. study of ASC30, showing placebo‑adjusted weight reductions of 5.4%, 7.0% and 7.7% at 13 weeks across three dose cohorts; the highest dose...

Kymera Therapeutics reported positive early‑stage results for KT‑621 in atopic dermatitis, with a Phase 1b BroADen study showing an average 63% reduction in Eczema Area and Severity Index (EASI)...

A deeper read of phase 3 data for BioNTech and OncoC4’s anti‑CTLA‑4 antibody confirmed a survival benefit but highlighted a challenging safety profile. Analysts and clinicians flagged tolerability...

Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics for $620 million upfront to obtain brelovitug, a monoclonal antibody in late‑stage development for chronic hepatitis D. The deal...

Dyne Therapeutics announced that its next‑generation exon‑skipping therapy for Duchenne muscular dystrophy met its late‑stage study endpoints, positioning the company to submit for regulatory...

Researchers presented pooled data at ASH indicating that minimal residual disease (MRD) negativity correlates with longer overall survival in acute myeloid leukemia and could serve as a surrogate...

Gilead Sciences and partner Arcellx reported pivotal‑stage data for anito‑cel in multiple myeloma showing high overall response rates and substantial complete remissions: 96% response and 74% CR...

Kallyope said elismetrep, its experimental acute migraine therapy, succeeded in a Phase 2b study and will advance to Phase 3. The mid‑stage win marks a decade‑old biotech’s first clear clinical...

Surgical teams implanted a genetically modified pig liver into a human recipient and demonstrated that the graft could perform key liver functions for an extended period before complications...

Researchers implanted a genetically modified pig liver into a human patient and demonstrated that the graft could support core liver functions for an extended period before complications forced...

Vertex reported early positive outcomes for its CRISPR-based therapy in children with blood disorders, and ASH briefings signaled broader industry momentum to extend one-time gene therapies into...

Gilead and partner Arcellx reported pivotal‑stage CAR‑T data showing deep and durable responses in multiple myeloma, with the companies citing high overall response rates and a large proportion of...

A large prospective pooled dataset presented at ASH found that multiparameter flow cytometry–based minimal residual disease (MRD) before consolidation correlates with longer overall survival in...

Natera presented real‑world data at ASH showing that circulating tumor DNA (ctDNA) positivity at end of treatment was prognostic across lymphoma subtypes and performed better than PET imaging for...

Cosmo Pharmaceuticals released topline results from two identical Phase III trials (SCALP 1 and SCALP 2) for clascoterone 5% solution in androgenetic alopecia and reported statistically...

Axoltis closed an $18 million Series A to advance NX210c, a cyclic peptide derived from an embryonic neuronal protein, through clinical development for amyotrophic lateral sclerosis (ALS). The...